Final Assault: Daiichi Sankyo Threatens Legal Action Against Former Ranbaxy Shareholders For Concealing Information
This article was originally published in PharmAsia News
Executive Summary
Breaking its silence after four years, Daiichi Sankyo hinted for the first time that it would pursue legal remedies against former shareholders of Ranbaxy, which the Japanese company bought in 2008 to expand into emerging markets and the generics drug space.